• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening

tetano

Editor, Senior Moderator
Cell Rep


. 2021 Aug 10;109627.
doi: 10.1016/j.celrep.2021.109627. Online ahead of print.
One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening


Irene M Francino-Urdaniz[SUP] 1 [/SUP], Paul J Steiner[SUP] 1 [/SUP], Monica B Kirby[SUP] 1 [/SUP], Fangzhu Zhao[SUP] 2 [/SUP], Cyrus M Haas[SUP] 1 [/SUP], Shawn Barman[SUP] 2 [/SUP], Emily R Rhodes[SUP] 1 [/SUP], Alison C Leonard[SUP] 1 [/SUP], Linghang Peng[SUP] 2 [/SUP], Kayla G Sprenger[SUP] 1 [/SUP], Joseph G Jardine[SUP] 3 [/SUP], Timothy A Whitehead[SUP] 4 [/SUP]



Affiliations

Abstract

The potential emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) escape mutants is a threat to the efficacy of existing vaccines and neutralizing antibody (nAb) therapies. An understanding of the antibody/S escape mutation landscape is urgently needed to preemptively address this threat. Here we describe a rapid method to identify escape mutants for nAbs targeting the S receptor binding site. We identified escape mutants for five nAbs, including three from the public germline class VH3-53 elicited by natural coronavirus disease 2019 (COVID-19) infection. Escape mutations predominantly mapped to the periphery of the angiotensin-converting enzyme 2 (ACE2) recognition site on the RBD with K417, D420, Y421, F486, and Q493 as notable hotspots. We provide libraries, methods, and software as an openly available community resource to accelerate new therapeutic strategies against SARS-CoV-2.

Keywords: S RBD; SARS-CoV-2; deep mutational scanning; escape mutants; neutralizing antibodies; yeast surface display.
 
Back
Top Bottom